ARIUS to Present at BioFinance 2005

TSX Venture Exchange: ARI

TORONTO, May 12 /CNW/ - ARIUS Research Inc. (TSX-VE: ARI) announced today
that it will present at BioFinance 2005, Canada's leading life sciences
investor conference, to be held May 17-19, 2005 at the Marriott Eaton Centre
Hotel in Toronto. Dr. David S. Young, President and Chief Scientific Officer
of ARIUS, will provide an update of recent developments at ARIUS on Wednesday,
May 18 at 4:30 p.m. in the Trinity II conference room.
Dr. Young will present the company's business plan and discuss the
FunctionFIRST(TM) platform, functional antibody library, and recent progress
towards scientific and business goals.
Recent highlights from ARIUS include six scientific presentations at the
American Association for Cancer Research in April, 2005, the issuance of a new
antibody patent, the extension of the Oxford BioMedica (LSE: OXB) research
collaboration to discover and characterize novel cancer targets and downstream
therapeutic products, and an investment by the Biotechnology Value Fund of San
Francisco, CA.

About ARIUS Research

ARIUS Research Inc. is a biotechnology company dedicated to the discovery
and development of novel anticancer monoclonal antibodies (MAbs). Established
in 1999, ARIUS has built a proprietary technology platform, FunctionFIRST(TM),
that rapidly identifies powerful MAbs targeting a variety of cancer
indications. This antibody generation engine has enabled ARIUS to assemble a
growing pipeline of over 250 functional MAbs, which may be used for commercial
collaborations, out-licensing or in-house development. ARIUS has ongoing
licensing and research partnerships with key biotechnology and drug
development companies that provide revenues and access to external
technologies. The long-term vision of ARIUS is to deliver personalized therapy
by matching multiple antibodies to the distinct antigenic characteristics of
each patient's tumor cells thereby increasing efficacy and avoiding side
effects.

Forward-Looking Statement

Certain statements in this news release constitute "forward-looking
statements" within the meaning of the Private Securities Litigation Reform Act
of 1995, which involve known and unknown risks, uncertainties and other
factors that may cause our actual results to be materially different from any
future results, performance or achievements expressed or implied by such
statements. Forward-looking statements in this release include, but are not
limited to, ARIUS successfully advancing its new product programs as well as
licensing opportunities. These statements are only predictions and actual
events or results may differ materially. Factors that could cause such actual
events or results expressed or implied by such forward-looking statements to
differ materially from any future results expressed or implied by such
statements include, but are not limited to: early stage of development;
technology and product development; dependence on and management of current
and future corporate collaborations; future capital needs; uncertainty of
additional funding; no assurance of market acceptance; dependence on
proprietary technology and uncertainty of patent protection; intense
competition; manufacturing and market uncertainties; and government
regulation. These and other factors are described in detail in the Company's
Annual Report, forthcoming news releases and other filings with Canadian
securities regulatory authorities and the U.S. Securities & Exchange
Commission. Forward-looking statements are based on our current expectations
and ARIUS is not obligated to update such information to reflect later events
or developments.


    The TSX Venture Exchange has not reviewed and does not accept
   responsibility for the adequacy or accuracy of this statement.